Geron Corporation (GON)
Summary
GON Chart
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $240 million.
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. GERN's management did not increase its 2026 revenue guidance, but did suggest revenues were likely to reach the mid- to high-end of that guidance. A potential competitor in myelofibrosis, KPTI, is looking to file for approval in frontline myelofibrosis, while GERN is running its phase 3 study in relapsed/refractory myelofibrosis.
Geron Corporation (GON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Geron Corporation ever had a stock split?
Geron Corporation Profile
| Biotechnology Industry | Healthcare Sector | Harout Semerjian CEO | XDUS Exchange | US3741631036 ISIN |
| US Country | 258 Employees | - Last Dividend | 22 Jul 2014 Last Split | 30 Jun 1996 IPO Date |
Overview
Geron Corporation stands out as a pivotal entity within the biopharmaceutical sector, primarily focusing its efforts on the advanced clinical development and potential commercialization of treatments targeting myeloid hematologic malignancies. Marking its inception in 1990, Geron Corporation has since dedicated itself to addressing the urgent need for innovative therapeutic options within this specialized area of oncology. The company’s strategic operations and research endeavors are centralized in its headquarters located in Foster City, California. Geron's commitment to the field is underscored by its relentless pursuit of groundbreaking therapeutic advancements, aiming to significantly impact patients' lives afflicted by these severe blood disorders.
Products and Services
Geron Corporation's developmental pipeline is focused primarily on the pioneering therapeutic candidate, imetelstat. This telomerase inhibitor represents a novel approach in the treatment of myeloid hematologic malignancies. The significance of imetelstat lies in its mechanism of action, which targets the root cause of disease proliferation at the cellular level. Below are the key areas of focus for Geron's imetelstat:
- Low or Intermediate-1 Risk Myelodysplastic Syndromes: Imetelstat is in Phase 3 clinical trials for treating patients diagnosed with low or intermediate-1 risk myelodysplastic syndromes (MDS). This group of disorders adversely affects the bone marrow's ability to produce healthy blood cells, leading to various complications. The ongoing trials aim to evaluate the efficacy of imetelstat in controlling disease progression, potentially altering the treatment landscape for MDS patients.
- Intermediate-2 or High-Risk Myelofibrosis: Another critical area under investigation involves patients with intermediate-2 or high-risk myelofibrosis. This rare, chronic blood cancer is characterized by the extensive scarring of bone marrow, which disrupts the body's normal production of blood cells. By inhibiting telomerase activity, imetelstat seeks to counteract the uncontrolled proliferation of malignant stem and progenitor cells that contribute to the disease state, offering hope for a therapeutic breakthrough in the management of myelofibrosis.
Contact Information
